Although mutations of various tumor-suppressor genes (e.g., APC, KRAS, p53) and oncogenes (e.g., cMYC) have been described in a high percentage of CRC (Dulak et al., 2012) (Powell et al., 1992), epigenetic and genetic alterations are likely to act synergistically in CRC development (Hammoud et al., 2013; Ying and Tao, 2009; Suzuki et al., 2004). Here, TP53 is linked to colorectal carcinoma.